Ticagrelor interactions
Full monograph for TicagrelorCheck it against another medicine
Medicines
303 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Apalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 39 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 6 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the…2 documented mechanisms | 7 sources — open the full entry |
| Mifepristone | Major | Synergy | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9… | 4 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9… | 4 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Phenobarbital | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Ponatinib Hydrochloride | Major | Synergy | Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 3 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Primidone | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Major | Synergy | Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 5 sources — open the full entry |
| Relugolix | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Rifampicin | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 3 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 1 sources — open the full entry |
| Trastuzumab Emtansine | Major | Synergy | Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs… | 40 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ticagrelor, which is primarily metabolized by the… | 6 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Moderate | Synergy | The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the… | 2 sources — open the full entry |
| Alteplase | Moderate | Synergy | The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the… | 2 sources — open the full entry |
Conditions
Conditions in which Ticagrelor needs care, as documented in this source.
Hemorrhage
MajorTicagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
1 source
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Liver Diseases
MajorTicagrelor is metabolized by the liver. The use of ticagrelor should be avoided in patients with severe hepatic impairment. Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment.
1 source
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Bradycardia
ModerateTicagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the postmarketing setting. It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.
1 source
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Dyspnea
ModerateDyspnea has been reported with the use of ticagrelor. Care should be taken when prescribing this drug to patients that experienced dyspnea. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible. In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.
1 source
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):
Kidney Diseases
ModerateNo dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied, close monitoring is recommended.
1 source
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):